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Background: Lanthanum carbonate (LC), an effective phosphate (P) binder, is widely used to manage
hyperphosphatemia in hemodialysis patients. However, the long-term safety of LC treatment in clinical practice
has not been completely established.
Methods: In an observational multicenter study, we retrospectively investigated the long-term tolerability in
Japanese hemodialysis patients who had completed a 3-year phase III extension study of LC. Among 39
patients who completed the phase III extension study, those who gave written informed consent to allow a
retrospective examination of their medical records for up to 8 years were enrolled. During the period spanning
2009 to 2013, a tolerability assessment was performed by monitoring adverse events, laboratory parameters,
and vital signs.
Results: Among the 34 enrolled patients, 30 were included for analysis. In this 5-year follow-up observational
study, 18 of 30 patients (60.0 %) received LC with or without some other P binders (PBs), 10 patients (33.3 %)
switched from LC to another PB, and 2 patients (6.7 %) did not use PB. During the phase III study, 16 patients
(53.3 %) experienced a drug-related adverse event, with the most common being gastrointestinal disorder,
already known to be a common adverse event of LC. No drug-related adverse events were reported during the
follow-up observational study. Five of 18 patients (27.8 %) who continued LC and 3 of 12 patients (25.0 %) who
did not continue LC experienced serious adverse events during the follow-up observational study. However,
none of these events except for constipation were drug-related.
Mean serum P concentrations was kept within the guideline-recommended management target range during
the study period. No clinically significant changes in laboratory parameters and vital signs were observed
except for pronounced decreases in intact parathyrois hormone (PTH) and blood pressure during the follow-up
observational study period.
Conclusions: In patients who completed a 3-year phase III extension study of LC, there was no evidence of
delayed adverse events or any increase in the incidence of LC-related adverse events with increasing LC
exposure for up to 8 years.
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In chronic kidney disease (CKD) patients, urinary ex-
cretion of phosphate (P) is compromised due to renal
failure, and hyperphosphatemia is therefore likely to
occur. When hyperphosphatemia persists for a pro-
longed period, the risk of cardiovascular disease due to
vascular calcification increases, resulting in extremely
poor patient prognosis [1–5]. Consequently, the long-
term management of the serum P concentration in dia-
lysis patients is considered to be an important risk
management item for improving patient prognosis. The
“Clinical Practice Guideline for the Management of
Chronic Kidney Disease-Mineral and Bone Disorder”
published by the Japanese Society for Dialysis Therapy
(JSDT) recommends that serum P concentrations be
managed within the range of 3.5 to 6.0 mg/dL [6].
Lanthanum carbonate (LC), an effective non-calcium
(Ca) P binder (PB), is widely used to manage hyperpho-
sphatemia in patients with CKD on dialysis. Studies
evaluating the efficacy and safety of LC administration
over 2, 3, and 6 years have consistently reported that
LC is well tolerated with no evidence of safety-related
issues [7–10]. Despite this evidence supporting its
safety, concerns over the long-term safety of LC persist
because some reports have suggested the potential risks
of lanthanum (La) deposition and toxicity in the gastro-
intestinal tract, bone, liver, and central nervous system
[11–15]. These safety concerns would appear to be at
least partially based on the known toxicities of alumin-
ium (Al)-containing P binders (PBs), which were com-
monly used between 1970 and 1990. Accumulation of
Al due to long-term use of these binders in patients
with CKD caused serious complications including en-
cephalopathy, osteomalacia, proximal myopathy and
microcytic anaemia [16]. Consequently, Al-containing
PBs were contraindicated in 1992 for use in dialysis pa-
tients. A recently reported systematic review and meta-
analysis of randomized controlled trials concluded that
LC is well tolerated and more effective than placebo on
a short-term basis in the treatment of hyperphosphate-
mia in dialysis patients, but its long-term tolerability
and safety still needs further investigation [17].
Therefore, in this observational multicenter study, we
retrospectively investigated long-term (for up to 8 years)
tolerability in Japanese hemodialysis patients who had
completed a 3-year clinical study of LC [10].
Methods
Study design and patients
This was a retrospective, observational multicenter
study conducted at 10 Japanese dialysis facilities in pa-
tients with end stage renal disease (ESRD) undergoing
hemodialysis and who had completed the 3-year phase
III extension study of LC. The phase III study consistedof the original 1-year open-label study [18] and an add-
itional 2-year open-label study [10]. One hundred and
forty-five patients were enrolled in the phase III study,
and after 1 year of treatment, 63 patients continued
with further LC treatment for up to 3 years [10].
Among the 39 hemodialysis patients who completed
the phase III study, patients who gave written informed
consent to allow the retrospective examination of their
medical records for up to 8 years (including the 3-year
period of the phase III study) were enrolled in this
follow-up observational study. Five patients who were
assigned to placebo during the 6-week double-blind
phase were excluded from being potential study candi-
dates. The original 1-year study was performed during
2005 and 2006, and an additional 2-year study was per-
formed from 2006 to 2008. The study period of this
follow-up observational study was from 2009 to 2013. The
study was registered in UMIN-CTR: UMIN000015227.Assessments
Using medical records, patient history including under-
lying diseases was examined at baseline of the phase III
study. The primary endpoint was incidence of adverse
events over a period of up to 8 years. Additionally, we
investigated changes in the dosage of LC and PB other
than LC and cinacalcet and the changes in biochemical
and hematologic parameters and vital signs.Statistical analysis
All variables were analysed by calculating descriptive sta-
tistics: frequency tables for categorical variables and the
mean, standard deviation (SD) for continuous variables.
The mean changes from baseline and their two-sided
95 % confidence intervals were calculated for laboratory
parameters and vital signs. Comparisons between con-
tinuous variables were performed using the Wilcoxon
signed-rank test and paired t test. In addition, we per-
formed an ANOVA test. A value of p < 0.05 was consid-
ered to be statistically significant.Ethics
The study was conducted in accordance with principles
that have their origin in the Declaration of Helsinki and
the Ethical Guidelines for Clinical Studies published by
Ministry of Health, Labour and Welfare. The central insti-
tutional review board at Wakayama Medical University
approved the study protocol, and written informed con-
sent was obtained from each patient before the enroll-
ment. The investigators retrospectively examined the
patients’ medical records in a manner that fully protected
the patients’ privacy.
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Study patients
Among the 34 patients who enrolled in this follow-up
observational study, 30 patients were included for ana-
lysis, and 4 patients whose data were not available were
excluded from analysis. The excluded patients consisted
of 2 patients lost to follow-up, 1 patient who had a renal
transplantation, and 1 patient who withdrew consent.
Table 1 shows the baseline demographic characteristics
of the 30 study patients. The average age was 54.7 years,
and the male/female ratio was 21/9. The mean time on
dialysis was 98.0 months, and the most common under-
lying disease was chronic glomerulonephritis, which was
present in 50.0 % of patients. A significant proportion of
patients had complications commonly associated with
dialysis such as renal anaemia, hypertension, and sec-
ondary hyperparathyroidism (86.7, 76.7, and 70.0 %, re-
spectively). The mean serum P, corrected Ca, and intact
parathyrois hormone (PTH) concentrations were 7.8,
9.3, and 283.1 pg/mL, respectively.
Changes in the dosage of phosphate binders and
cinacalcet
Following manufacturing and marketing approval in
October 2008, LC was launched onto the market inTable 1 Baseline demographic characteristics of the study patients
Total (n = 30)
Age (year) 54.7 ± 10.9
Sex
Male (n) 21 (61.8 %)
Female (n) 9 (26.5 %)
Dry weight (kg) 62.4 ± 7.4 (Male)
50.6 ± 8.3 (Female)
Time on dialysis (months) 98.0 ± 82.3
Underlying diseases causing renal failure
Chronic glomerulonephritis (n) 15 (50.0 %)
Diabetic nephropathy (n) 8 (26.7 %)
Chronic pyelonephritis (n) 2 (6.7 %)
IgA nephropathy (n) 2 (6.7 %)
Polycystic kidney (n) 2 (6.7 %)
Focal sclerosing glomerulonephritis (n) 1 (3.3 %)
Complications
Renal anemia (n) 26 (86.7 %)
Hypertension (n) 23 (76.7 %)
Secondary hyperparathyroidism (n) 21 (70.0 %)
Serum P (mg/dL) 7.8 ± 1.6
Serum corrected Ca (mg/dL) 9.3 ± 0.6
Serum intact PTH (pg/mL) 283.1 ± 152.4
Data are given as mean ± standard deviation or number
P phosphate, Ca calciumMarch 2009. This meant that LC had not been released
for general clinical use during the final stages of the
phase III study. Thus, LC could not be used for a cer-
tain period until it was adopted by dialysis facilities fol-
lowing its release onto the market.
The mean dose of LC at the start of the phase III study
was 1700.0 ± 879.4 mg/day. This dosage was generally
maintained during the phase III study, but was reduced
following the phase III study because 18 of 30 patients
(60.0 %) received LC with or without some other PBs
such as Ca carbonate or sevelamer hydrochloride. In 10
of 30 patients (33.3 %), the PB was switched from LC to
another PB, and in 2 of 30 patients (6.7 %) PB was no
longer used. After cinacalcet was launched in January
2008, there was a steady yearly increase in the number
of patients receiving this drug during the follow-up ob-
servational study. The mean dose of cinacalcet at the
start of the follow-up observational study was 40.0 ±
12.9 mg/day, and this dose was generally maintained for
the duration of the study (Table 2).
Incidence of adverse events
Drug (LC)-related adverse events that occurred during
the phase III study are listed in Table 3. Sixteen patients
(53.3 %) experienced a drug-related adverse event during
the phase III study. None of the 30 patients experienced
any drug-related (any PB including LC) adverse events
during the 5-year follow-up observational study.
A total of 16 patients experienced 103 cases of drug-
related adverse events, but all of these events except for
1 event were not serious. The 1 serious adverse event
was constipation reported as “worsening of constipation”
by the investigator and which resolved without treat-
ment. The most common drug-related adverse events
were nausea and vomiting, which occurred in 12 pa-
tients (40.0 %).
Serious adverse events that occurred during the phase
III study and 5-year follow-up observational study are
listed in Table 4. None of these serious adverse events
except 1 event (constipation mentioned above) were
drug-related. There were 3 deaths. The causes of death
were cardiac failure (2 cases) and 1 case of pneumonia.
Two patients (6.7 %) experienced a serious adverse event
during the phase III study. During the 5-year follow-up
observational study, 5 of 18 patients (27.8 %) who con-
tinued LC use and 3 of 12 patients (25.0 %) who did not
continue LC (10 patients switched to another PB and 2
patients did not use PB) experienced serious adverse
events.
Mean serum P concentrations
Figure 1 shows the changes from baseline (at the start of
phase III study) in mean serum P concentrations during
the 8-year study period. Mean serum P concentrations
Table 2 Dosage changes in phosphate binders and cinacalcet
Phase III study (1-year study and additional 2-year study) 5-year follow-up observational study

































































































Table 3 Drug-related adverse events during the phase III study
Drug-related adverse events
(SOC/PT)
Patients with events, 16/30 (53.3 %)






Abdominal discomfort 4 4
Abdominal pain, upper 3 5
Diarrhoea 2 7
Constipation 2 2
Abdominal pain, lower 1 1
Faeces, soft 1 1
General disorders and administration site conditions
Flank pain 1 9
Chest discomfort 1 1
Investigations
C-reactive protein increased 1 1
SOC System Organ Class, PT Preferred Term (MedDRA ver. 18.0)
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3 years and 5.3 mg/dL after 8 years, thus remaining
within the management target range (3.5–6.0 mg/dL)
recommended in the JSDT guidelines [6] during the en-
tire study period (Fig. 1a). The mean serum P concentra-
tion in patients who continued LC use did not differ
significantly from that observed in the patients who did
not continue LC (Fig. 1b).
Laboratory parameters and vital signs
Laboratory parameters and vital signs of all patients are
shown in Table 5. Several parameters and vital signs
showed statistically significant changes after 4 or 8 years.
Of those parameters, the decrease in intact PTH and
blood pressure would appear to be clinically significant.
The mean changes from baseline after 8 years were
−103.45 pg/mL, −18.83 mmHg (systolic blood pressure
(SBP)), and −13.39 mmHg (diastolic blood pressure
(DBP)), respectively. Table 6 shows the laboratory pa-
rameters and vital signs of patients who continued to re-
ceive LC. In those patients, the summary statistics did
not differ from those observed in all patients.
Discussion
LC is widely used to manage hyperphosphatemia in
patients with CKD on dialysis and has contributed to
improved clinical outcomes in these patients. The
short-term safety profile of LC has been reported [19];
the most common adverse events of LC- and Ca-containing PB were gastrointestinal reactions. No sig-
nificant difference was found in nausea (RR 1.72, 95 %
CI 1.00–2.98, p = 0.05), vomiting (RR 2.17, 95 % CI
0.87–5.41, p = 0.10), diarrhoea (RR 1.26, 95 % CI 0.84–
1.89, p = 0.27), or constipation (RR 0.78, 95 % CI 0.50–
1.21, p = 0.27) between the two treatments.
Some studies were evaluated the efficacy, tolerability,
and safety of LC monotherapy over 2 years [7], 3 years
[8], and 6 years [9] have consistently reported that LC is
well tolerated, with no evidence of safety concerns. The
majority of LC adverse drug reactions were related to
the gastro-intestinal tract (mainly nausea, diarrhoea, and
flatulence) [9] and are primarily mild/moderate in sever-
ity, consistent with those observed with other phosphate
binders. However, there is no insufficient safety data for
a prolonged period or for Japanese.
Accordingly, the authors think that it is important to
accumulate more evidence of the long-term effects of
LC treatment in the clinical practice and explore how
LC can be used for a prolonged period in a safe and ap-
propriate manner.
Therefore, we retrospectively investigated the long-
term tolerability of LC among Japanese hemodialysis pa-
tients who completed the phase III study study of LC
treatment, in an observational multicenter study in order
to follow safety outcomes for further 5 years regardless
of these patients’ LC administration. In this follow-up
observational study, 18 of 30 patients (60.0 %) received
LC with or without some other PBs, and in 10 of 30 pa-
tients (33.3 %), the PB was switched from LC to another
PB and in 2 of 30 patients (6.7 %) PB was no longer used.
During the phase III study, LC-related adverse events
occurred in 16 patients (53.3 %); however, no adverse
events that were considered by the investigators to be
related to any PB, including LC, were reported during
the 5-year follow-up observational study. Although the
dosage of LC was reduced in some patients and other
patients switched to another PB from LC after the phase
III study, these results strongly suggest that no evidence
exists of delayed adverse events after 3 years of LC ex-
posure or any increase in the incidence of LC-related ad-
verse events with increasing LC exposure.
The most common drug-related adverse events that
occurred during the phase III study were vomiting and
nausea, which are already known to be common adverse
events associated with LC [20]; however, there were no
treatment discontinuations due to gastrointestinal ad-
verse events. Hutchison et al. reported that no gastro-
intestinal events occurred in US patients after 3 years of
LC exposure or in European patients after 4 years of ex-
posure [9]. These results indicate that long-term LC
treatment is possible provided gastrointestinal events
that tend to occur more frequently in the early phase of
treatment can be controlled.
Table 4 Serious adverse events during the phase III study and 5-year follow-up observational study
Patients who continue LC Patients who did not continue LC
















Pyelonephritis acute 1 1
Neoplasms benign, malignant, and unspecified (including cysts and polyps)
Colon cancer 1 1
Nervous system disorder
Cerebral haemorrhage 1 1
Cardiac disorders
Myocardial ischaemia 1 1
Tachycardia 1 1
Cardiac valve disease 1 1
Cardiac failure 1 1
Cardiac failure acute 1a 1
Vascular disorders
Peripheral arterial occlusive disease 2 2 1 1
Gastrointestinal disorders
Constipation 1 1
Upper gastrointestinal haemorrhage 1 1
Surgical and medical procedures
Foot amputation 1 1




Fig. 1 Mean serum P concentrations at the start of phase III study and at various time points over the 8-year period covered by the study. a All
patients, b Patients who continued LC or did not continue LC. Data are given as mean ± standard deviation (n = number of patients in a specific year)
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Table 5 Laboratory parameters and vital signs of all patients
Parameters Start 4 years after 8 years after 4 years mean change ± SEM
(95 % CI)
8 years mean change ± SEM
(95 % CI)
P (mg/dL) 7.8 ± 1.6 5.8 ± 1.0*** 5.3 ± 1.2*** −2.19 ± 0.29 (−2.80, −1.59)*** −.51 ± 0.35 (−3.24, −1.79)***
Corrected Ca (mg/dL) 9.3 ± 0.6 9.2 ± 0.5 9.4 ± 0.6 −0.11 ± 0.13 (−0.38, 0.16) 0.11 ± 0.11 (−0.12, 0.34)
Intact PTH (pg/mL) 283.1 ± 152.4 180.7 ± 126.6*** 179.1 ± 131.7* −103.95 ± 27.20 (−160.55, −47.35)*** −103.45 ± 43.91 (−194.76, −12.14)*
Na (mEq/L) 139.2 ± 3.0 138.5 ± 2.4 138.3 ± 3.3* −0.89 ± 0.62 (−2.17, 0.38) −1.20 ± 0.66 (−2.56, 0.16)*
K (mEq/L) 5.0 ± 0.7 5.4 ± 0.7 5.0 ± 0.8 0.39 ± 0.10 (0.19, 0.60) −0.05 ± 0.13 (−0.33, 0.22)
Cl (mEq/L) 100.8 ± 3.4 102.9 ± 3.6 102.0 ± 3.4 1.85 ± 0.79 (0.23, 3.47) 1.07 ± 0.83 (−0.63, 2.78)
Glucose (mg/dL) 128.6 ± 51.9 123.9 ± 53.3 113.9 ± 37.2 17.00 ± 23.91 (−37.08, 71.08) 2.90 ± 8.10 (−15.43, 21.23)
CRP (mg/dL) 0.2 ± 0.2 0.6 ± 1.3 0.6 ± 1.0 0.29 ± 0.19 (−0.11, 0.70) 0.37 ± 0.22 (−0.09, 0.83)
RBC (×104/μL) 327 ± 39 356 ± 32 361 ± 36 0.31 ± 0.08 (0.15, 0.47) 0.34 ± 0.08 (0.18, 0.50)
WBC (/μL) 5803 ± 1474 6190 ± 2028 5891 ± 1977 0.44 ± 0.28 (−0.13, 1.01) 0.16 ± 0.27 (−0.40, 0.71)
Hb (g/dL) 10.5 ± 1.1 11.2 ± 1.3 10.8 ± 1.1 0.48 ± 0.26 (−0.04, 1.01) 0.26 ± 0.26 (−0.28, 0.79)
Ht (%) 31.8 ± 3.6 34.7 ± 2.6 33.9 ± 2.6 3.00 ± 0.73 (1.51, 4.51) 2.06 ± 0.70 (0.62, 3.49)
Plt (×104/μL) 19.8 ± 4.4 19.7 ± 6.6 20.2 ± 6.7 0.03 ± 1.04 (−2.21, 2.18) 2.06 ± 0.70 (0.62, 3.49)
Serum Alb (g/dL) 4.0 ± 0.3 3.9 ± 0.3* 3.6 ± 0.3*** −0.13 ± 0.05 (−0.23, −0.02)* −0.43 ± 0.06 (−0.56, −0.31)***
ALP (U/L) 237.3 ± 110.1 242.6 ± 85.0 262.9 ± 95.1 2.19 ± 18.32 (−35.54, 39.92) 10.88 ± 17.59 (−25.34, 47.12)
LDH (IU/L) 168.0 ± 30.5 173.9 ± 33.5 195.5 ± 47.4 5.65 ± 6.52 (−7.86, 19.16) 23.91 ± 7.45 (8.46, 39.37)
AST (U/L) 11.7 ± 6.4 10.9 ± 4.2 17.8 ± 16.5 −0.85 ± 1.27 (−3.47, 1.76) 5.85 ± 3.31 (−0.95, 12.65)
ALT (U/L) 10.7 ± 5.5 10.3 ± 7.2 13.7 ± 8.5 −0.37 ± 1.76 (−3.99, 3.25) 2.85 ± 1.80 (−0.84, 6.55)
γ GTP (U/L) 20.5 ± 12.6 26.1 ± 31.5 28.2 ± 19.1 8.46 ± 6.75 (−5.51, 22.43) 9.38 ± 3.66 (1.81, 16.94)
Total bilirubin (mg/dL) 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.04 ± 0.02 (−0.01, 0.09) 0.05 ± 0.03 (−0.01, 0.12)
Creatinine (mg/dL) 12.7 ± 2.0 12.3 ± 1.8 11.2 ± 2.0*** −0.30 ± 0.33 (−0.98, 0.37) −1.40 ± 0.32 (−2.07, −0.74)***
Uric acid (mg/dL) 8.5 ± 1.2 8.0 ± 1.5 7.7 ± 1.4** −0.44 ± 0.31 (−1.09, 0.21) −0.84 ± 0.32 (−1.50, −0.17)**
BUN (mg/dL) 72.1 ± 12.0 69.6 ± 12.5 62.6 ± 16.6** −0.99 ± 3.02 (−7.21, 5.22) −9.81 ± 2.90 (−15.78, −3.84)**
BUN after dialysis (mg/dL) 23.6 ± 7.0 20.0 ± 5.7** 16.8 ± 6.0*** −3.85 ± 1.37 (−6.68, −1.02)** −7.39 ± 1.32 (−10.1, −4.66)***
TG (mg/dL) 132.0 ± 66.0 121.8 ± 76.7 110.2 ± 46.3 10.53 ± 18.02 (−27.33, 48.38) −5.11 ± 10.69 (−27.57, 17.36)
Total cholesterol (mg/dL) 178.0 ± 33.4 161.8 ± 37.9 171.0 ± 39.2 −7.56 ± 5.43 (− 19.13, 4.00) −2.00 ± 8.45 (−20.01, 16.01)
HDL-C (mg/dL) 45.5 ± 14.4 51.0 ± 14.2 53.6 ± 16.9 5.16 ± 2.27 (0.40, 9.92) 6.42 ± 2.29 (1.62, 11.2)
SBP (mmHg) 160.2 ± 24.4 144.2 ± 21.4*** 146.2 ± 18.5*** −19.13 ± 5.19 (−29.89, −8.37)*** −18.83 ± 4.81 (−28.80, −8.86)***
DBP (mmHg) 88.7 ± 16.5 79.6 ± 12.6** 77.4 ± 13.2*** −10.26 ± 3.69 (−17.92, −2.6)** −13.39 ± 2.25 (−18.06, −8.73)***
HR (beats/min) 77.1 ± 12.0 74.8 ± 16.9 75.0 ± 13.3 −2.26 ± 2.79 (−8.13, 3.61) −2.74 ± 3.00 (−9.04, 3.57)
Data are given as mean ± standard deviation (n)
CI confidence interval
V.S. At the start, ***P < 0.001, **P < 0.01, *P < 0.05
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toxicity in bone, liver, and the central nervous system
[11–15]. The long-term safety profile of LC in hemo-
dialysis patients receiving treatment for up to 6 years
have been reported and appear to show no evidence of
adverse effects on the liver, bone, or the central ner-
vous system [9].
Two patients (6.7 %) during the phase III study, 5 of
18 patients (27.8 %) who continued LC use and 3 of 12
patients (25.0 %) who did not continue LC experienced
a serious adverse event during the 5 year follow-up ob-
servational study; however, all of these events except for
1 were not drug-related. The types of serious adverseevents are those peculiar to dialysis patients with mul-
tiple complications. There was no difference in fre-
quency of serious adverse events between patients who
continued LC and patients who did not continue LC.
La deposition in a mesenteric lymph node found at
autopsy of an ESRD patient 3 years after LC administra-
tion was reported [21]. Although the clinical significance
of this deposition of La is not clear, further investigation
of its potential long-term toxic effects is needed. Thus,
the long-term safety of LC treatment, especially in clin-
ical practice, has not been completely established. In re-
cent years, several case reports about La deposition in
gastric mucosa have been published [22–25]. Although
Table 6 Laboratory parameters and vital signs of patients who continued LC use
Parameters Start 1 year after 2 years after 3 years after 4 years after 5 years after 6 years after 7 years after 8 years after
P (mg/dL) 8.4 ± 1.3 5.0 ± 1.0*** 5.4 ± 0.9*** 5.1 ± 0.9*** 5.7 ± 0.7*** 5.7 ± 0.9*** 5.5 ± 1.3*** 6.0 ± 1.5*** 5.5 ± 1.3***
Corrected Ca (mg/dL) 9.2 ± 0.6 9.6 ± 0.6 9.6 ± 0.6 9.9 ± 0.8 9.2 ± 0.5 9.1 ± 0.6 9.2 ± 0.5 9.3 ± 0.5 9.3 ± 0.7
Intact PTH (pg/mL) 334.6 ± 164.4 319.0 ± 185.3 353.4 ± 186.2 372.2 ± 228.2 218.9 ± 141.2** 204.3 ± 136.4* 225.2 ± 126.5* 185.7 ± 111.6* 200.9 ± 133.1*
Na (mEq/L) 138.9 ± 3.4 138.9 ± 2.3 139.1 ± 3.3 139.4 ± 2.3 138.3 ± 2.3 137.7 ± 2.5 138.4 ± 3.0 137.3 ± 3.0* 138.8 ± 2.7
K (mEq/L) 5.1 ± 0.8 5.1 ± 0.7 5.3 ± 0.6 5.2 ± 0.7 5.4 ± 0.6 5.1 ± 0.7 5.4 ± 0.7 5.3 ± 0.4 5.1 ± 0.7
Cl (mEq/L) 100.4 ± 3.8 100.4 ± 3.0 100.8 ± 3.8 100.9 ± 3.4 101.9 ± 3.6 100.6 ± 3.5 101.1 ± 4.1 99.3 ± 2.9 101.2 ± 3.4
Glucose (mg/dL) 129.0 ± 62.1 121.6 ± 47.7 121.4 ± 40.9 132.6 ± 73.1 139.3 ± 63.9 125.4 ± 38.2 132.2 ± 54.8 143.4 ± 103.2 108.1 ± 34.2
CRP (mg/dL) 0.2 ± 0.2 0.2 ± 0.2 0.1 ± 0.1 0.2 ± 0.2 1.0 ± 1.7 0.8 ± 1.2 0.5 ± 0.9 0.7 ± 1.2 0.8 ± 1.2
RBC (×104/μL) 331 ± 39 348 ± 35 344 ± 28 340 ± 35 356 ± 36 380 ± 82 360 ± 30 358 ± 41 362 ± 40
WBC (/μL) 5800 ± 1229 6067 ± 1435 5856 ± 1574 6089 ± 1386 6533 ± 2061 6782 ± 2136 5911 ± 1945 6349 ± 2030 6126 ± 1841
Hb (g/dL) 10.6 ± 1.0 10.9 ± 1.0 10.6 ± 0.9 10.6 ± 1.0 11.1 ± 0.8 11.1 ± 1.0 11.0 ± 0.8 10.4 ± 1.1 11.0 ± 1.0
Ht (%) 32.0 ± 3.9 33.0 ± 2.7 32.4 ± 2.3 32.4 ± 3.2 34.3 ± 3.1 34.7 ± 3.1 34.2 ± 2.4 32.5 ± 3.1 33.8 ± 2.8
Plt (×104/μL) 21.3 ± 4.3 21.5 ± 3.2 21.0 ± 4.2 21.4 ± 4.6 22.0 ± 6.2 22.3 ± 6.1 21.3 ± 5.8 23.1 ± 5.9 21.6 ± 6.9
Serum Alb (g/dL) 4.1 ± 0.2 4.0 ± 0.2 4.1 ± 0.2 3.9 ± 0.3 3.9 ± 0.3 3.8 ± 0.2 3.9 ± 0.3 3.8 ± 0.2 3.6 ± 0.3
ALP (U/L) 238.8 ± 129.5 290.1 ± 145.1 307.2 ± 166.1 333.9 ± 216.4 228.8 ± 83.4 244.6 ± 80.7 258.1 ± 102.5 254.9 ± 99.5 270.7 ± 107.9
LDH (IU/L) 172.2 ± 33.4 165.4 ± 25.9* 170.1 ± 26.8 172.2 ± 30.3 175.4 ± 36.7 176.2 ± 35.4 189.8 ± 48.8 192.3 ± 43.0 199.1 ± 56.9
AST (U/L) 11.3 ± 6.8 10.7 ± 4.3 11.9 ± 3.4 15.2 ± 10.9 11.1 ± 3.8 13.1 ± 4.0 14.3 ± 4.5 15.6 ± 6.1 19.9 ± 19.8
ALT (U/L) 10.3 ± 5.9 9.8 ± 4.3 11.2 ± 7.2 12.5 ± 10.7 11.1 ± 9.0 12.4 ± 5.2 14.6 ± 7.4 16.1 ± 11.0 15.7 ± 9.7
γ GTP (U/L) 18.7 ± 9.7 18.5 ± 8.6 34.2 ± 63.4 29.1 ± 34.5 28.9 ± 38.8 29.4 ± 27.4 26.8 ± 19.2 27.6 ± 21.7 29.7 ± 20.8
Total bilirubin (mg/dL) 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.0 0.3 ± 0.1
Creatinine (mg/dL) 13.1 ± 1.9 13.2 ± 1.9 12.7 ± 1.9 12.3 ± 2.0 12.4 ± 1.9 12.3 ± 1.6* 11.8 ± 1.7** 11.7 ± 2.1** 11.5 ± 2.2***
Uric acid (mg/dL) 8.5 ± 1.3 8.3 ± 1.0 8.4 ± 1.0 8.1 ± 1.1 8.1 ± 1.8 8.3 ± 1.1 8.2 ± 1.4 8.2 ± 1.6 8.0 ± 1.5
BUN (mg/dL) 76.1 ± 10.5 74.6 ± 12.2 72.2 ± 13.8 66.5 ± 12.3** 69.4 ± 12.1* 72.2 ± 14.5 71.8 ± 13.2 67.2 ± 9.7** 66.7 ± 14.9*
BUN after dialysis (mg/dL) 25.8 ± 6.4 24.6 ± 5.5 22.8 ± 5.5 20.8 ± 5.4** 20.7 ± 5.8** 20.5 ± 6.8** 20.6 ± 5.8** 18.8 ± 4.7*** 18.5 ± 5.2***
TG (mg/dL) 131.6 ± 70.3 145.4 ± 86.4 156.4 ± 83.9 125.3 ± 72.5 134.5 ± 95.6 130.6 ± 69.3 114.5 ± 49.9 128.1 ± 74.7 114.3 ± 48.5
Total cholesterol (mg/dL) 175.4 ± 33.6 166.4 ± 30.9 181.1 ± 39.8 170.2 ± 31.8 157.5 ± 27.6 159.3 ± 46.5 182.4 ± 38.1 185.3 ± 40.1 176.7 ± 38.0
HDL-C (mg/dL) 44.5 ± 15.3 43.4 ± 12.6 44.3 ± 11.8 46.1 ± 13.8 52.7 ± 15.3 49.3 ± 13.1 54.5 ± 11.9 49.6 ± 12.4 50.0 ± 13.7
SBP (mmHg) 162.4 ± 23.2 160.1 ± 21.9 157.2 ± 22.8 153.3 ± 17.4** 149.8 ± 16.6* 149.5 ± 23.6** 150.9 ± 17.9* 141.3 ± 22.5** 144.2 ± 17.6**
DBP (mmHg) 92.9 ± 17.4 89.1 ± 17.5 86.4 ± 17.2** 86.8 ± 15.3* 84.9 ± 10.5* 82.6 ± 15.2*** 83.5 ± 12.5** 77.6 ± 12.9** 79.6 ± 12.6***
HR (beats/min) 78.1 ± 11.2 78.4 ± 9.9 79.1 ± 10.0 75.9 ± 9.6 77.1 ± 18.4 78.2 ± 12.0 74.7 ± 12.3 77.0 ± 14.8 76.9 ± 10.4
Data are given as mean ± standard deviation (n)
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tric mucosa, there is no relationship to gastrointestinal
symptoms. In a nod to these reports, further long-term
and large number observation should be needed.
Although several laboratory parameters showed sta-
tistically significant changes after 4 or 8 years, none of
these parameters except for intact PTH and blood pres-
sure were clinically significant when the mean changes
from baseline and their confidence intervals are taken
into account. At the start of the follow-up observational
study (2009), a pronounced decrease of more than
100 pg/mL in intact PTH was observed. This decrease
may be due to the introduction of cinacalcet in 2008.
Both systolic blood pressure (SBP) and diastolic blood
pressure (DBP) also decreased significantly after 3 years.
Although it is unknown why a clinically significant
decrease in blood pressure was observed, the degree of de-
crease in SBP and DBP after 8 years (i.e. SBP −18.83 mmHg,
DBP −13.39 mmHg) was a positive effect.
The serum P concentrations were maintained within the
management target range (3.5–6.0 mg/dL) recommended
in the JSDT guidelines [6] for the entire 8 years. The long-
term therapeutic effects of LC and other PBs on hyper-
phosphatemia were also confirmed in this study.
Hyperphosphatemia has been shown to increase mor-
tality among patients with CKD [26]. Given this finding,
management of serum P in patients with CKD has been
recognized as a treatment priority. Recent data suggest
improved survival when PB is used in the dialysis of pa-
tients [27, 28]. The results of other studies also suggest
that there is a survival benefit associated with LC treat-
ment [29, 30].
The present study has several limitations, the first of
which is selection bias. We selected the patients who
had completed the phase III study of LC, so we cannot
exclude the possibility that only patients with no safety
issues were enrolled in the study. Another potential limi-
tation, as with any other long-term follow-up study, is
the small number of enrolled patients. Regardless of
these limitations, the results of the present study re-
vealed no evidence of delayed adverse events or any in-
crease in the incidence of LC-related adverse events
with increasing LC exposure.
This study was might not able to put out the conclu-
sion to safety about LC, as there were a limited number
of the cases available. However, these results are valuable
to evaluate LC exposure for up to 8 years.
Conclusions
In patients who completed the 3-year phase III extension
study of LC, no drug-related adverse events were reported
during the follow-up observational study. Both patients
who continued LC use and patients who switched to an-
other PB experienced serious adverse events during thefollow-up observational study; however, there was no dif-
ference in the frequency of these events in either group
and no unexpected serious adverse events were observed.
The observations reported so far are short-term, and none
of them cover a period of more than 10 years. Thus, it ap-
pears that further detailed investigations are needed.
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